ProShare Advisors
IBIO icon

ProShare Advisors’s iBio IBIO Stock Holding History

ProShare Advisors’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-81
Closed -$17K – 1946
2022
Q1 		$17K Sell
81
-13
-14% -$2.72K ﹤0.01% 2183
2021
Q4 		$25K Buy
94
+39
+71% +$14.9K ﹤0.01% 2322
2021
Q3 		$29K Sell
55
-57
-51% -$35.5K ﹤0.01% 1992
2021
Q2 		$85K Sell
112
-2
-2% -$1.46K ﹤0.01% 2311
2021
Q1 		$88K Buy
114
+34
+43% +$29.6K ﹤0.01% 2179
2020
Q4 		$42K Buy
+80
New +$65.2K ﹤0.01% 2059

Other funds holding IBIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ProShare Advisors's IBIO Position: Q2 2022 in Review

ProShare Advisors sold out of iBio (IBIO) in Q2 2022, closing a stake of 81 shares — an estimated $17K sold.

ProShare Advisors first reported a position in IBIO in Q4 2020 and held it in 6 quarters. The position peaked at $88K in Q1 2021. 53 funds tracked by Wall St. Rank hold IBIO as of Q2 2022.

  • ProShare Advisors reported no remaining iBio position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 81 iBio shares in Q2 2022, an estimated $17K.
  • ProShare Advisors first reported a position in iBio in Q4 2020 and held it in 6 quarters.
  • ProShare Advisors's iBio position peaked at $88K in Q1 2021.
  • 53 funds tracked by Wall St. Rank held iBio as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.